Drug Trial Radar · NCT04301076
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 31, 2021
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Mar 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.
Conditions
- Acute Adult T-Cell Leukemia/Lymphoma
- Adult T-Cell Leukemia/Lymphoma
- Chronic Adult T-Cell Leukemia/Lymphoma
- HTLV-1 Infection
Interventions
Biospecimen CollectionProcedure
Undergo tissue and blood sample collection
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Computed TomographyProcedure
Undergo PET/CT or CT
CyclophosphamideDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
EtoposideDrug
Given IV
LenalidomideDrug
Given PO
Multigated Acquisition ScanProcedure
Undergo MUGA
Positron Emission TomographyProcedure
Undergo PET/CT
PrednisoneDrug
Given PO
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: Up to the end of induction therapy
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri · Recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Siteman Cancer Center-South County
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey · Recruiting
Memorial Sloan Kettering Monmouth
Middletown, New Jersey · Recruiting
Memorial Sloan Kettering Bergen
Montvale, New Jersey · Recruiting
Memorial Sloan Kettering Commack
Commack, New York · Recruiting
Memorial Sloan Kettering Westchester
Harrison, New York · Recruiting
NYU Langone Hospital - Long Island
Mineola, New York · Suspended
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Suspended
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
NYP/Weill Cornell Medical Center
New York, New York · Suspended
Memorial Sloan Kettering Nassau
Uniondale, New York · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.